secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001193125-25-311957
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vor Biopharma reprices employee stock options to $8.18; CEO gets 4.16M options repriced
--------------------------------------------------------------------------------

- Board reduced exercise price of ~5.2M underwater options to $8.18, the Dec 5, 2025 closing price.
- Repriced options originally ranged from $17.80 to $47.60; CEO Jean-Paul Kress repriced 4,164,831 options.
- Retention period ends Dec 5, 2027; options exercised earlier retain original exercise price.
- CFO Sandy Mahatme received option for 1,388,274 shares at $17.80, reducing to $8.18 after retention period.
- Repricing aims to retain employees and avoid dilution from new equity grants or cash comp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525311957/0001193125-25-311957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525311957/vor-20251205.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-311957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer